When was Bioextrax founded?

Bioextrax was founded in 2014 and raised its 1st funding round 8 years after it was founded.

Where is Bioextrax located?

Bioextrax is headquartered in Lund, Sweden.

Who is the current CEO of Bioextrax?

Mohamad Takwa of Bioextrax. They have also founded 1 company.

How many employees does Bioextrax have?

As of Aug 31, 2026, the latest employee count at Bioextrax is 25.

Is Bioextrax a funded company?

Bioextrax is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round on Jun 01, 2022.

When was the latest funding round of Bioextrax?

Bioextrax's latest funding was a $***** Grant (prize money) round on Jun 01, 2022, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In Sweden, the Life Sciences Platforms and Tools sector has seen $42.2M in funding in 2026 to date.

Where does Bioextrax rank among its competitors?

Bioextrax ranks 1092nd amongst 1975 active competitors, of which 450 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Bioextrax?

Bioextrax's top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Bioextrax - 2026 Company Profile, Team, Funding & Competitors

Company Details

Bioextrax has developed a technology, which uses a microbial strain to extract PHA granules from PHA-producing bacteria. The technology uses mild lysis of the microbial cell wall to extract a proprietary isolate from the microbe. The isolate, in turn, extracts PHA granules from the bacteria and produces a by-product protein hydrolysate. Also, the company claims that the by-products and the microbial isolate can be used for several other things.

Key Metrics

Founded Year

2014

Location

Lund, Sweden

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Jun 01, 2022, $*****

Investors

Europa & 2 more

Ranked

1092^nd among 1975 active competitors

Employee Count

25 as on Aug 31, 2026

Similar Companies

Antheia & 2682 more

View Bioextrax's full profile

Bioextrax has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Jun 01, 2022 for $*****. 1 investor participated in its latest round. Bioextrax has 3 institutional investors.

Here is the list of recent funding rounds of Bioextrax:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 01, 2022	9140473	Grant (prize money)	2138524	9253364	4408912	6089528

Access funding benchmarks and valuations. Sign up today!

View details of Bioextrax's funding rounds and investors

The founders of Bioextrax are Mohamad Takwa and Kristofer Cook.

Here are the details of Bioextrax's key team members:

Mohamad Takwa: Co-Founder & CEO of Bioextrax and founder of 2 other companies, Glycolink and Avsalt.
Kristofer Cook: Former Co-Founder of Bioextrax and founder of 2 other companies, Bioprocess Control and Carbiotix.

View details of Bioextrax's Founder profiles and Board Members

Bioextrax's employee count trend

Bioextrax has 25 employees as of Aug 26. Here is Bioextrax's employee count trend over the years:

Uncover Bioextrax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bioextrax include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Bioextrax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
6th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
7th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
8th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
1092nd	Bioextrax 2014, Lund (Sweden), Funding Raised	Tool for PHA extraction from bacteria	-	Europa, Capitral & 1 others	26/100